SAN FRANCISCO--(BUSINESS WIRE)--Carmot Therapeutics today announced two key additions to its Board of Directors and Management team.
"We are delighted to welcome Aetna to Carmot’s Board and Elena to our senior management team as the company advances its growing metabolic disease pipeline toward the clinic,” said CEO Stig Hansen. “Together, they bring extensive experience in metabolic disease and business development that will be great assets to our company."
Dr. Trombley joins Carmot Therapeutics Board of Directors as an independent director. She is Vice President, Chief Operating Officer of NGM Biopharmaceuticals. She joined NGM as head of Business Development in 2011. She was most recently from Novartis in Basel, Switzerland, where she was Chief of Staff for the Chief Executive Officer and worked on key corporate initiatives and strategic projects across the company’s healthcare businesses. Previously, she was Associate Director, Business Development at XenoPort, Inc. (NASDAQ: XNPT), where her responsibilities also included strategic and portfolio planning in addition to various out-licensing projects. Prior to XenoPort, she was a Senior Engagement Manager at McKinsey & Company, where she advised pharmaceutical and medical device clients on strategic, commercial and operational issues. She received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from MIT.
Elena Viboch, Director of Business Development and Operations, joins Carmot from FLX Bio, where she served as Senior Manager of Corporate Development and Strategy. Prior to FLX Bio, Elena Viboch worked in New Product Planning with Jazz Pharmaceuticals. Previously, she worked in healthcare investing with Kearny Venture Partners where Ms. Viboch was closely involved in multiple new investments in public and private biopharmaceutical companies. She began her career as a consultant to pharmaceutical companies with Putnam Associates. Ms. Viboch has an MBA from Harvard Business School where she graduated with High Distinction as a Baker Scholar and a B.A. from Swarthmore College with Honors.
About Carmot Therapeutics, Inc.
Carmot Therapeutics is pioneering the discovery and development of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot’s vision is to become a leader in drug discovery by generating superior drugs for challenging therapeutic targets. Chemotype Evolution, Carmot’s proprietary technology, enables the rapid identification of novel drugs through an evolutionary discovery paradigm and has produced a pipeline of breakthrough therapeutics currently in pre-clinical development. Over the past few years, Carmot has built Chemotype Evolution into a robust technology that has yielded novel lead compounds targeting incretin receptors (GLP-1R and GIP-R) for the treatment of Type 2 diabetes, obesity, and NASH and protein-protein interactions (NEMO/IKK) for the treatment of cancer and inflammation. Carmot plans to enter Phase 1 clinical testing in 2017 with a novel, differentiated dual GLP-1/GIP receptor agonist.
Stig Hansen, Ph.D., 415-978-2176